Abstract
A new generation of antithrombotic agents, which are conventionally known as direct oral anticoagulants (DOACs), have recently emerged and are continuing to be developed. These provide direct inhibition of either thrombin (factor IIa; FIIa) or activated factor X (FXa) and currently include dabigatran (FIIa inhibitor) and rivaroxaban, apixaban, and edoxaban (FXa inhibitors). The dogma that DOACs do not require laboratory monitoring is countered by ongoing recognition that laboratory testing for drug effects is needed in many situations. In this review, we summarize the background to establishment of DOACs, assess which tests were found to be useful to screen for or quantitate drug effects/levels, and then review published guidelines/recommendations to assess concordance. In brief, (a) for the anti-FIIa agent dabigatran, the recommended screening assays are activated partial thromboplastin time (APTT) and/or thrombin time (TT), and the quantitative assays (using a dabigatran standard) are dilute TT/direct thrombin inhibitor assay (Hemoclot thrombin inhibitor) or an ecarin-based assay such as the ecarin clot time (ECT); (b) for the anti-FXa agent rivaroxaban, the recommended screening assay is the prothrombin time (PT), but this was not endorsed by all guidelines, and the quantitative assay (using a specific rivaroxaban standard) is an anti-FXa assay; (c) for the anti-FXa agent apixaban, the general insensitivity of PT and APTT prevented most groups from providing recommendation, and instead there was generalized support for direct quantitative assessment using anti-FXa assays and specific apixaban standard; (d) there is insufficient data for other direct anti-FXa agents and limited guidance in the literature.
References
1. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl):7S–47S.10.1378/chest.1412S3Search in Google Scholar
2. Lippi G, Franchini M, Favaloro EJ. Pharmacogenetics of vitamin K antagonists: useful or hype? Clin Chem Lab Med 2009;47:503–15.10.1515/CCLM.2009.140Search in Google Scholar
3. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants – the present and the future. Pathology 2011;43:682–92.10.1097/PAT.0b013e32834bf5f4Search in Google Scholar
4. Eby C. Warfarin pharmacogenetics: does more accurate dosing benefit patients? Semin Thromb Hemost 2012;38:661–6.10.1055/s-0032-1326789Search in Google Scholar
5. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62.10.1016/S0140-6736(13)62343-0Search in Google Scholar
6. Bonar RA, Favaloro EJ, Marsden K. External quality assurance for heparin monitoring. Semin Thromb Hemost 2012;38:632–9.10.1055/s-0032-1321954Search in Google Scholar PubMed
7. Favaloro EJ, Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med (Zagreb) 2012;22:329–41.Search in Google Scholar
8. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014;12:320–8.10.1111/jth.12485Search in Google Scholar PubMed
9. Loke YK, Pradhan S, Yeong JK, Kwok CS. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol 2014. doi: 10.1111/bcp.12376. [Epub ahead of print 11 Mar 2014].10.1111/bcp.12376Search in Google Scholar PubMed PubMed Central
10. Lippi G, Favaloro EJ, Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? Semin Thromb Hemost 2014. doi: 10.1055/s-0034-1381233. [Epub ahead of print 11 Jun 2014].10.1055/s-0034-1381233Search in Google Scholar PubMed
11. Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against? Clin Chem Lab Med 2011;49:755–7.10.1515/CCLM.2011.126Search in Google Scholar PubMed
12. Harenberg J, Kraemer S, Du S, Giese C, Schulze A, Kraemer R, et al. Determination of direct oral anticoagulants from human serum samples. Semin Thromb Hemost 2014;40:129–34.Search in Google Scholar
13. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116–27.10.1160/TH09-11-0758Search in Google Scholar PubMed
14. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008;100:453–61.10.1160/TH07-12-0714Search in Google Scholar
15. Becker RC, Alexander JH, Newby LK, Yang H, Barrett Y, Mohan P, et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost 2010;104:976–83.10.1160/TH10-04-0247Search in Google Scholar PubMed
16. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50: 743–53.10.1177/0091270009351883Search in Google Scholar PubMed
17. Gous T, Couchman L, Patel JP, Paradzai C, Arya R, Flanagan RJ. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit 2014. [Epub ahead of print 1 Apr 2014].10.1097/FTD.0000000000000059Search in Google Scholar PubMed
18. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012;107:985–97.10.1160/TH11-11-0804Search in Google Scholar PubMed
19. Avecilla ST, Ferrell C, Chandler WL, Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol 2012;137:572–4.10.1309/AJCPAU7OQM0SRPZQSearch in Google Scholar PubMed
20. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105:371–8.10.1160/TH10-06-0342Search in Google Scholar PubMed
21. Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012;38:16–22.10.1055/s-0031-1300947Search in Google Scholar PubMed
22. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;23:138–43.10.1097/MBC.0b013e32834f1b0cSearch in Google Scholar PubMed
23. Douxfils J, Dogné JM, Mullier F, Chatelain B, Rönquist-Nii Y, Malmström RE, et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013;110:543–9.10.1160/TH13-03-0202Search in Google Scholar PubMed
24. Hapgood G, Butler J, Malan E, Chunilal S, Tran H. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 2013;110:308–15.10.1160/TH13-04-0301Search in Google Scholar PubMed
25. Antovic JP, Skeppholm M, Eintrei J, Boija EE, Söderblom L, Norberg EM, et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 2013;69:1875–81.10.1007/s00228-013-1550-4Search in Google Scholar PubMed
26. Gosselin RC, Dwyre DM, Dager WE. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother 2013;47:1635–40.10.1177/1060028013509074Search in Google Scholar PubMed
27. Lippi G, Ardissino D, Quintavalla R, Cervellin G. Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation. A tentative approach based on routine laboratory tests. J Thromb Thrombolysis 2014;38:269–74.10.1007/s11239-014-1082-5Search in Google Scholar PubMed
28. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogné JM. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012;130:956–66.10.1016/j.thromres.2012.09.004Search in Google Scholar PubMed
29. Tripodi A. Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test. J Thromb Haemost 2013;11:576–8.10.1111/jth.12166Search in Google Scholar PubMed
30. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011;9:133–9.10.1111/j.1538-7836.2010.04098.xSearch in Google Scholar PubMed
31. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, et al. Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor. Thromb Haemost 2010;103:815–25.10.1160/TH09-03-0176Search in Google Scholar PubMed
32. Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost 2012;38:178–84.10.1055/s-0032-1301415Search in Google Scholar PubMed
33. Samama MM. Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay. J Thromb Haemost 2013;11:579–80.10.1111/jth.12165Search in Google Scholar PubMed
34. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012;107:379–87.10.1160/TH11-06-0391Search in Google Scholar PubMed
35. Harenberg J, Marx S, Kramer R, Giese C, Weiss C. Determination of an international sensivitity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis 2011;22:637–41.10.1097/MBC.0b013e328349f1d6Search in Google Scholar PubMed
36. Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013;110:283–94.10.1160/TH12-12-0898Search in Google Scholar PubMed
37. Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost 2014;111:240–8.10.1160/TH13-06-0470Search in Google Scholar PubMed
38. Barrett YC, Wang Z, Knabb RM. A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost 2013;19:522–8.10.1177/1076029612441859Search in Google Scholar PubMed
39. Harenberg J, Du S, Weiss C, Krämer R, Hoppensteadt D, Walenga J; working party: methods to determine apixaban of the Subcommittee on Control of Anticoagulation of the International Society of Thrombosis and Haemostasis. Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH. J Thromb Haemost 2014;12:801–4.10.1111/jth.12547Search in Google Scholar PubMed
40. Lippi G, Favaloro EJ, Simundic AM. Biomedical research platforms and their influence on article submissions and journal rankings: an update. Biochem Med (Zagreb) 2012;22:7–14.10.11613/BM.2012.002Search in Google Scholar
41. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013. doi: 10.1111/jth.12149. [Epub ahead of print 24 Jan 2013].10.1111/jth.12149Search in Google Scholar PubMed
42. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e44S–88S.10.1378/chest.11-2292Search in Google Scholar PubMed PubMed Central
43. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al.; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719–47.Search in Google Scholar
44. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34:2094–106.10.1093/eurheartj/eht134Search in Google Scholar PubMed
45. Ward C, Conner G, Donnan G, Gallus A, McRae S. Practical management of patients on apixaban: a consensus guide. Thromb J 2013;11:27.10.1186/1477-9560-11-27Search in Google Scholar PubMed PubMed Central
46. Government of South Australia. Dabigatran Clinical Guidelines. Updated: 23 Jan 2014. Available from: http://www.sahealth.sa.gov.au/wps/wcm/connect/eea3550048fb0a5f895afd7675638bd8/Dabigatran+Clinical+Guidelines+Feb+2012_PHCS-MTPP-201302.pdf?MOD=AJPERES&CACHEID=eea3550048fb0a5f895afd7675638bd8. Accessed 29 Apr 2014.Search in Google Scholar
47. Tran H, Joseph J, Young L, McRae S, Curnow J, Nandurkar H, et al. New oral anticoagulants – a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Intern Med J 2014;44:525–36.10.1111/imj.12448Search in Google Scholar PubMed
48. Tripodi A, Di Iorio G, Lippi G, Testa S, Manotti C. Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL. Clin Chem Lab Med 2012;50:2137–40.10.1515/cclm-2012-0327Search in Google Scholar PubMed
49. Baglin T, Keeling D, Kitchen S; British Committee for Standards in Haematology. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012;159:427–9.10.1111/bjh.12052Search in Google Scholar PubMed
50. Swedish Society on Thrombosis and Haemostasis (SSTH). Clinical recommendations for treatment with new oral anticoagulants. Available from: http://ssth.se/documents/vp/vpeng120213.pdf. Accessed 29 Apr 2014.Search in Google Scholar
51. Favaloro EJ, Bonar R, Butler J, Marsden K. Laboratory testing for the new oral anticoagulants: a review of current practice. Pathology 2013;45:435–7.10.1097/PAT.0b013e328360f02dSearch in Google Scholar PubMed
52. Bonar R, Favaloro EJ, Marsden K; RCPAQAP Haematology Haemostasis Committee. Dabigatran special exercise report. Issued April 2014. St Leonards, NSW, Australia: RCPA Quality Assurance Program.Search in Google Scholar
53. Favaloro EJ, Plebani M, Lippi G. Regulation in hemostasis and thrombosis: part I – in vitro diagnostics. Semin Thromb Hemost 2013;39:235–49.10.1055/s-0033-1336833Search in Google Scholar PubMed
54. Di Minno A, Spadarella G, Prisco D, Franchini M, Lupoli R, Di Minno MN. Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review. Semin Thromb Hemost 2013;39:840–6.10.1055/s-0033-1354423Search in Google Scholar PubMed
55. Exner T, Ellwood L, Rubie J, Barancewicz A. Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study. Thromb Haemost 2013;109:762–5.Search in Google Scholar
56. Altman R, Gonzalez CD. Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs. Thromb J 2014;12:7.10.1186/1477-9560-12-7Search in Google Scholar PubMed PubMed Central
57. Harenberg J, Krämer S, Du S, Zolfaghari S, Schulze A, Krämer R, et al. Measurement of rivaroxaban and apixaban in serum samples of patients. Eur J Clin Invest 2014;44: 743–52.10.1111/eci.12291Search in Google Scholar PubMed PubMed Central
58. Harenberg J, Du S, Krämer S, Giese C, Schulze A, Weiss C, et al. Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples. Semin Thromb Hemost 2013;39:66–71.Search in Google Scholar
©2015 by De Gruyter
